Emerging antibodies for the treatment of multiple myeloma

References

• Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15(6):361–370.
   PubMed Web of Science ®Google Scholar
• Weidle UH, Tiefenthaler G, Weiss EH, et al. The intriguing options of multispecific antibody formats for treatment of cancer. Cancer Genomics Proteomics. 2013;10(1):1–18.
   PubMed Web of Science ®Google Scholar
• Sapra P, Shor B. Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacol Ther. 2013;138(3):452–469.
   PubMed Web of Science ®Google Scholar
• Markham A. Elotuzumab: first global approval. Drugs. 2016;76(3):397–403.
   Google Scholar
• McKeage K. Daratumumab: first global approval. Drugs. 2016;76(2):275–281.
   PubMed Web of Science ®Google Scholar
• SEER Stat Fact Sheets: Myeloma [Internet]. [cited 2016 Jan 27]. Available from: http://seer.cancer.gov/statfacts/html/mulmy.html
   Google Scholar
• Moreau P, San Miguel J, Ludwig H, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi133–vi137.
   PubMed Web of Science ®Google Scholar
• Moreau P, Avet-Loiseau H, Harousseau JL, et al. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol. 2011;29:1898–1906.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–917.
   PubMed Web of Science ®Google Scholar
• Pönisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol. 2006;132:205–212.
   PubMed Web of Science ®Google Scholar
• Zagouri F, Terpos E, Kastritis E, et al. An update on the use of lenalidomide for the treatment of multiple myeloma. Expert Opin Pharmacother. 2015;16(12):1865–1877.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691–4695.
   PubMed Web of Science ®Google Scholar
• Lemieux E, Hulin C, Caillot D, et al. Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma. Biol Blood Marrow Transplant. 2013;19:445–449.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892–3901.
   PubMed Web of Science ®Google Scholar
• San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055–1066.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 8;372(2):142–152.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014;15(13):1417–1418.
   Google Scholar
• Chanan-Khan AA, Borrello I, Lee KP, et al. Development of target-specific treatments in multiple myeloma. Br J Haematol. 2010;151(1):3–15.
   PubMed Web of Science ®Google Scholar
• Misso G, Zappavigna S, Castellano M, et al. Emerging pathways as individualized therapeutic target of multiple myeloma. Expert Opin Biol Ther. 2013 Jun;13(Suppl 1):S95–S109.
   PubMed Web of Science ®Google Scholar
• Lonial S, Durie B, Palumbo A, et al. Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. Leukemia. 2016;30(3):526–535.
   Web of Science ®Google Scholar
• Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 2004;103:3148–3157.
   PubMed Web of Science ®Google Scholar
• Moreaux J, Cremer FW, Reme T, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood. 2005;106:1021–1030.
   PubMed Web of Science ®Google Scholar
• Descamps G, Wuillème-Toumi S, Trichet V, et al. CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642. J Immunol. 2006;177:4218–4223.
   PubMed Web of Science ®Google Scholar
• Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14:2775–2784.
   PubMed Web of Science ®Google Scholar
• Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112:1329–1337.
   PubMed Web of Science ®Google Scholar
• Balasa B, Yun R, Belmar NA, et al. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways. Cancer Immunol Immunother. 2015;64(1):61–73.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Szmania SM, Dillon M, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009;8(9):2616–2624.
   PubMed Web of Science ®Google Scholar
• Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120(3):552–559.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Jagannath S, Moreau P, et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015;2(12):e516–e527.
   PubMed Web of Science ®Google Scholar
• Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30(16):1953–1959.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. Elotuzumab is an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–631.
   PubMed Web of Science ®Google Scholar
• Berdeja J, Jagannath S, Zonder J, et al. Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a phase Ib study. Clin Lymphoma Myeloma Leuk. 2016;16(3):129–138.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Sexton R, Ailawadhi S, et al. Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211. Blood Cancer J. 2015;5:e334.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012;30(16):1960–1965.
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Chen Q, Small GW, et al. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol. 2009;145:481–490.
   PubMed Web of Science ®Google Scholar
• van Zaanen HCT, Lokhorst HM, Aarden LA, et al. Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and solublegp130. Leuk Lymphoma. 1998;31:551–558.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Gercheva L, Williams C, et al. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol. 2015;90:42–49.
   PubMed Web of Science ®Google Scholar
• San-Miguel J, Bladé J, Shpilberg O, et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood. 2014;123(26):4136–4142.
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Manges RF, Sonneveld P, et al. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2013;161(3):357–366.
   PubMed Web of Science ®Google Scholar
• Hirata T, Shimazaki C, Sumikuma T, et al. Humanized anti-interleukin-6 receptor monoclonal antibody induced apoptosis of fresh and cloned human myeloma cells in vitro. Leuk Res. 2003;27(4):343–349.
   PubMed Web of Science ®Google Scholar
• Matsuyama Y, Nagashima T, Honne K, et al. Successful treatment of a patient with rheumatoid arthritis and IgA-κ multiple myeloma with tocilizumab. Intern Me. 2011;50(6):639–642.
   PubMed Web of Science ®Google Scholar
• Allegra A, Penna G, Alonci A, et al. Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. Eur J Haematol. 2013;90(6):441–468.
   PubMed Web of Science ®Google Scholar
• Fulciniti M, Hideshima T, Vermot-Desroches C, et al. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009;15(23):7144–7152.
   PubMed Web of Science ®Google Scholar
• Moreau P, Voillat L, Benboukher L, et al. Rituximab in CD20 positive multiple myeloma. Leukemia. 2007;21(4):835–836.
   PubMed Web of Science ®Google Scholar
• Zojer N, Kirchbacher K, Vesely M, et al. Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leuk Lymphoma. 2006;47:1103–1109.
   PubMed Web of Science ®Google Scholar
• Baz R, Fanning S, Kunkel L, et al. Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma. Leuk Lymphoma. 2007;48(12):2338–2344.
   PubMed Web of Science ®Google Scholar
• Musto P, Carella AM Jr, Greco MM, et al. Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation. Br J Haematol. 2003;123(4):746–747.
   PubMed Web of Science ®Google Scholar
• Lebovic D, Kaminski MS, Anderson TB, et al. A phase II study of consolidation treatment with iodione-131 tositumomab (BexxarTM) in multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts). 2012;120:1854.
   Google Scholar
• Stein R, Smith MR, Chen S, et al. Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines. Clin Cancer Res. 2009;15(8):2808–2817.
   PubMed Web of Science ®Google Scholar
• Kaufman JL, Niesvizky R, Stadtmauer EA, et al. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. Br J Haematol. 2013;163(4):478–486.
   PubMed Web of Science ®Google Scholar
• de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840–1848.
   PubMed Web of Science ®Google Scholar
• van der Veer MS, de Weers M, van Kessel B, et al. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J. 2011;1(10):e41.
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207–1219.
   PubMed Web of Science ®Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):155–160.
   PubMed Web of Science ®Google Scholar
• Moreau P, Mateos MV, Blade J, et al. An open-label, multicenter, phase 1b study of daratumumab in combination with backbone regimens in patients with multiple myeloma. Blood. 2014;124:176.
   PubMed Web of Science ®Google Scholar
• Chari A, Lonial S, Suvannasankha A, et al. Open-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide and dexamethasone in patients with at least 2 lines of prior therapy and relapsed or relapsed and refractory multiple myeloma. Blood. 2015;126(Suppl 23). Abstract no. 506.
   Google Scholar
• Deckert J, Wetzel MC, Bartle LM, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res. 2014;20(17):4574–4583.
   PubMed Web of Science ®Google Scholar
• Jiang H, Acharya C, An G, et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016. 2016;30(2):399–408.
   Web of Science ®Google Scholar
• Martin TG, Hsu K, Strickland SA, et al. A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma. J Clin Oncol. 2014;32:5s. (suppl; abstr 8532).
   PubMed Web of Science ®Google Scholar
• Martin TG, Baz R, Benson DM, et al. A phase Ib dose escalation trial of SAR650984 (anti-CD38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma. Blood. 2014;124:83.
   Google Scholar
• Raab S, Goldschmidt HM, Agis H, et al. A phase I/IIa study of the human anti-CD38antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM). J Clin Oncol. 2015;33S:8574.
   Google Scholar
• Hassan SB, Sørensen JF, Olsen BN, et al. Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacol Immunotoxicol. 2014 Apr;36(2):96–104.
   PubMed Web of Science ®Google Scholar
• Bensinger W, Maziarz RT, Jagannath S, et al. A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br J Haematol. 2012;159(1):58–66.
   PubMed Web of Science ®Google Scholar
• Hussein M, Berenson JR, Niesvizky R, et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica. 2010;95(5):845–848.
   PubMed Web of Science ®Google Scholar
• Tai YT, Li XF, Catley L, et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 2005;65(24):11712–11720.
   Web of Science ®Google Scholar
• Agura E, Niesvizky R, Matous J, et al. Dacetuzumab (SGN-40), lenalidomide, and weekly dexamethasone in relapsed or refractory multiple myeloma: multiple responses observed in a phase 1b study. Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 2870.
   Google Scholar
• Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(12):1788–1795.
   PubMed Web of Science ®Google Scholar
• Ria R, Vacca A, Russo F, et al. A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. Thromb Haemost. 2004;92(6):1438–1445.
   PubMed Web of Science ®Google Scholar
• Koldehoff M, Beelen DW, Elmaagacli AH. Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma. J Leukoc Biol. 2008;84(2):561–576.
   PubMed Web of Science ®Google Scholar
• Markovina S, Callander NS, O’Connor SL, et al. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. Mol Cancer. 2010;9:176.
   PubMed Web of Science ®Google Scholar
• Somlo G, Lashkari A, Bellamy W, et al. Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial. Br J Haematol. 2011;154(4):533–535.
   PubMed Web of Science ®Google Scholar
• White D, Kassim A, Bhaskar B, et al. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer. 2013;119(2):339–347.
   PubMed Web of Science ®Google Scholar
• Callander NS, Markovina S, Juckett MB, et al. The addition of bevacizumab (B) to lenalidomide (L) and low dose dexamethasone does not significantly increase response in relapsed or refractory multiple myeloma [abstract 3885]. Blood (ASH Annual Meeting Abstracts). 2009;114:1495.
   Web of Science ®Google Scholar
• Mahtouk K, Jourdan M, De Vos J, et al. An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. Blood. 2004;103(5):1829–1837.
   PubMed Web of Science ®Google Scholar
• Böll B, Eichenauer DA, Von Tresckow B, et al. Activity of cetuximab as single agent in a patient with relapsed multiple myeloma. Leuk Lymphoma. 2010;51:562–564.
   PubMed Web of Science ®Google Scholar
• Von Tresckow B, Boell B, Eichenauer D, et al. Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial. Leuk Lymphoma. 2014;55:695–697.
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Alsina M, Fonseca R, et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol. 2008;26:3196–3203.
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Bianconi M, Maccaroni E, et al. Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr Opin Mol Ther. 2010;12:361–371.
   PubMedGoogle Scholar
• Descamps G, Gomez-Bougie P, Venot C, et al. A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45. Br J Cancer. 2009;100(2):366–369.
   PubMed Web of Science ®Google Scholar
• Moreau P, Cavallo F, Leleu X, et al. Phase I study of the anti-insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma. Leukemia. 2011;25(5):872–874.
   PubMed Web of Science ®Google Scholar
• Hengeveld PJ, Kersten MJ. B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy? Blood Cancer J. 2015;5:e282.
   PubMed Web of Science ®Google Scholar
• Raje N, Faber EA, Paul G, et al. Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma. Blood (ASH Annual Meeting Abstracts). 2012;120:Abstract 447.
   Google Scholar
• Xia Y, Medeiros LJ, Young KH. Immune checkpoint blockade: releasing the brake towards hematological malignancies. Blood Rev. 2015. Epub ahead of print.
   PubMedGoogle Scholar
• Cheah CY, Fowler NH, Neelapu SS. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. Curr Opin Oncol. 2015;27:384–391.
   PubMed Web of Science ®Google Scholar
• Ayed AO, Chang L-J, Moreb JS. Immunotherapy for multiple myeloma: current status and future directions. Crit Rev Oncol Hematol. 2015;96:399–412.
   PubMed Web of Science ®Google Scholar
• Kretz-Rommel A, Qin F, Dakappagari N, et al. Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol. 2008;180:699–705.
   PubMed Web of Science ®Google Scholar
• Conticello C, Giuffrida R, Parrinello N, et al. CD200 expression in patients with Multiple Myeloma: another piece of the puzzle. Leuk Res. 2013;37:1616–1621.
   PubMed Web of Science ®Google Scholar
• Tai Y-T, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7:1187–1199.
   PubMed Web of Science ®Google Scholar
• Harada T, Ozaki S. Targeted therapy for HM1.24 (CD317) on multiple myeloma cells. Biomed Res Int. 2014;2014:965384.
   PubMed Web of Science ®Google Scholar
• Maes K, De Smedt E, Kassambara A, et al. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma. Oncotarget. 2015;6:3319–3334.
   PubMed Web of Science ®Google Scholar
• Sprynski AC, Hose D, Caillot L, et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood. 2009;113:4614–4626.
   PubMed Web of Science ®Google Scholar